Objective: The aim of this review is to present the historical development and method of chorionic villus sampling (CVS) with a specific look on the changing trends in Norway. Background: In Norwegian law, the Biotechnology Act of 2003 regulates all prenatal diagnostics. Prenatal diagnostics is divided into two sub-groups: non-invasive and invasive. Method: A literature search in McMaster Plus and Medline was performed in June 2016, and in January 2017 using the words ”chorionic villus sampling”, ”CVS” and ”prenatal diagnostics”. Data from OUS-Rikshospitalet and Ullevål was used to describe CVS rates since it was introduced in Norway in 1986. Data was also collected from the Norwegian Health Directorate and “SSB” – Statistics of Norway. Results and conclusion: CVS refers to a procedure in which chorionic tissue (placenta) is obtained for prenatal genetic diagnosis. It is considered an invasive test with an associated risk of fetal loss between 0.22% - 1.00%. The method was first introduced in 1969 as a transcervical endoscopic technique. Later, the method was developed into a procedure performed under real-time ultrasound guidance. It was not until 1984 that the procedure was performed transabdominally. Today chorionic tissue can be obtained both transabdominally and transcervically. The numbers from OUS show that CVS rates has been kept on a steady level the last 5 years, despite an overall decrease in the use of invasive tests. This is most likely due to an increased use of ultrasound early in pregnancy and the need for early available genetic information from the fetus.